Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Enterprise Value (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Enterprise Value data on record, last reported at -$4.6 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 55.15% year-over-year to -$4.6 million; the TTM value through Sep 2025 reached -$4.6 million, down 55.15%, while the annual FY2024 figure was -$2.2 million, 2.3% down from the prior year.
  • Enterprise Value reached -$4.6 million in Q3 2025 per NWBO's latest filing, down from -$4.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$1.4 million in Q2 2023 and bottomed at -$15.2 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$5.1 million, with a median of -$4.3 million recorded in 2025.
  • Peak YoY movement for Enterprise Value: plummeted 877.49% in 2021, then skyrocketed 70.52% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$15.2 million in 2021, then surged by 54.08% to -$7.0 million in 2022, then soared by 69.48% to -$2.1 million in 2023, then decreased by 2.3% to -$2.2 million in 2024, then plummeted by 109.66% to -$4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$4.6 million in Q3 2025, -$4.3 million in Q2 2025, and -$2.8 million in Q1 2025.